Nonmotor symptoms in Parkinson's disease: classification and management

References

• Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNS Spectr. 2006;11(7):541–554.
   Web of Science ®Google Scholar
• Simuni T, Sethi K. Nonmotor manifestations of Parkinson’s disease. Ann Neurol. 2008;64(Suppl 2):S65–S80.
   Google Scholar
• Lim SY, Lang AE. The nonmotor symptoms of Parkinson’s disease – an overview. Mov Disord. 2010;25 Suppl 1:S123–S130.
   Google Scholar
• Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012;27(5):617–626.
   PubMed Web of Science ®Google Scholar
• The National Institute for Clinical Excellence (NICE). Parkinson’s disease: diagnosis and management in primary and secondary care. Clinical guideline 35. 2006. Available at: https://www.nice.org.uk/guidance/cg35/chapter/introduction. Accessed November 30, 2014.
   Google Scholar
• Global Parkinson’s Disease Survey Steering Committee. Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord. 2002;17(1):60–67.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938–942.
   PubMed Web of Science ®Google Scholar
• Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–312.
   PubMed Web of Science ®Google Scholar
• Findley L, Aujla M, Bain PG, et al. Direct economic impact of Parkinson’s disease: a research survey in the United Kingdom. Mov Disord. 2003;18(10):1139–1145.
   PubMed Web of Science ®Google Scholar
• Hagell P, Nordling S, Reimer J, Grabowski M, Persson U. Resource use and costs in a Swedish cohort of patients with Parkinson’s disease. Mov Disord. 2002;17(6):1213–1220.
   PubMed Web of Science ®Google Scholar
• Pressley JC, Louis ED, Tang MX, et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology. 2003;60(1):87–93.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Picillo M, et al. Link between non-motor symptoms and cognitive dysfunctions in de novo, drug-naive PD patients. J Neurol. 2012;259(9):1808–1813.
   Web of Science ®Google Scholar
• Khoo TK, Yarnall AJ, Duncan GW, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013;80(3):276–281.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord. 2007;13 Suppl:S2–S7.
   PubMed Web of Science ®Google Scholar
• Ray Chaudhuri K, Rojo JM, Schapira AH, et al. A proposal for a comprehensive grading of Parkinson’s disease severity combining motor and non-motor assessments: meeting an unmet need. PLoS One. 2013;8(2):e57221.
   Web of Science ®Google Scholar
• Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson’s disease: a cluster analysis on newly diagnosed untreated patients. PLoS One. 2013;8(8):e70244.
   PubMed Web of Science ®Google Scholar
• Erro R, Picillo M, Vitale C, et al. Non-motor symptoms in early Parkinson’s disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry. 2013;84(1):14–17.
   Web of Science ®Google Scholar
• Antonini A, Barone P, Marconi R, et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. J Neurol. 2012;259(12):2621–2631.
   PubMed Web of Science ®Google Scholar
• Picillo M, Erro R, Amboni M, et al. Gender differences in non-motor symptoms in early Parkinson’s disease: a 2-years follow-up study on previously untreated patients. Parkinsonism Relat Disord. 2014;20(8):850–854.
   Web of Science ®Google Scholar
• Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–474.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Park SY, Cho YJ, et al. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J Neurol Sci. 2009;287(1–2):200–204.
   PubMed Web of Science ®Google Scholar
• Kulisevsky J, García-Sánchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord. 2000;15(4):613–626.
   PubMed Web of Science ®Google Scholar
• Fera F, Nicoletti G, Cerasa A, et al. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson’s disease. Brain Res Bull. 2007;74(1–3):75–83.
   Web of Science ®Google Scholar
• Mitra T, Naidu Y, Martinez-Martin P, et al. The non declaration of non motor symptoms of Parkinson’s disease to healthcare professionals. An international survey using the NMSQuest. 6th International Congress on Mental Dysfunctions and other Non-motor Features in Parkinson’s disease and Related Disorders. Dresden October, 2008. Park Related Disorders P0II:161.
   Google Scholar
• Martinez-Martin P, Schapira AH, Stocchi F, et al. Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord. 2007;22(11):1623–1629.
   PubMed Web of Science ®Google Scholar
• Martinez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson’s disease: MDS-UPDRS and NMS Scale. Eur J Neurol. Apr 22. doi: 10.1111/ene.12165. [Epub ahead of print].
   Google Scholar
• Fasano A, Daniele A, Albanese A. Treatment of motor and non-motor features of Parkinson’s disease with deep brain stimulation. Lancet Neurol. 2012;11(5):429–442.
   PubMed Web of Science ®Google Scholar
• Asahina M, Vichayanrat E, Low DA, Iodice V, Mathias CJ. Autonomic dysfunction in parkinsonian disorders: assessment and pathophysiology. J Neurol Neurosurg Psychiatry. 2013;84(6):674–680.
   PubMed Web of Science ®Google Scholar
• Barone P, Antonini A, Colosimo C, et al; PRIAMO study group. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24(11):1641–1649.
   PubMed Web of Science ®Google Scholar
• Salat-Foix D, Andrews CN, Meddings J, Suchowersky O. Gastrointestinal symptoms in Parkinson disease: clinical aspects and management. Can J Neurol Sci. 2011;38(4):557–564.
   PubMed Web of Science ®Google Scholar
• Meningaud JP, Pitak-Arnnop P, Chikhani L, Bertrand JC. Drooling of saliva: a review of the etiology and management options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;101(1):48–57.
   PubMed Web of Science ®Google Scholar
• Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology. 2003;61(9):1279–1281.
   Web of Science ®Google Scholar
• Cersosimo MG, Raina GB, Pecci C, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J Neurol. 2013;260(5):1332–1338.
   PubMed Web of Science ®Google Scholar
• Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57(3):456–462.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Healy DG, Schapira AH; National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5(3):235–245.
   PubMed Web of Science ®Google Scholar
• Kapoor S, Bourdoumis A, Mambu L, Barua J. Effective management of lower urinary tract dysfunction in idiopathic Parkinson’s disease. Int J Urol. 2013;20(1):79–84.
   Web of Science ®Google Scholar
• Campeau L, Soler R, Andersson KE. Bladder dysfunction and parkinsonism: current pathophysiological understanding and management strategies. Curr Urol Rep. 2011;12(6):396–403.
   PubMedGoogle Scholar
• Picillo M, Amboni M, Erro R, et al. Gender differences in non-motor symptoms in early, drug naïve Parkinson’s disease. J Neurol. 2013;260(11):2849–2855.
   Web of Science ®Google Scholar
• Gao X, Chen H, Schwarzschild MA, et al. Erectile function and risk of Parkinson’s disease. Am J Epidemiol. 2007;166(12):1446–1450.
   PubMed Web of Science ®Google Scholar
• Okun MS, Walter BL, McDonald WM, et al. Beneficial effects of testosterone replacement for the nonmotor symptoms of Parkinson disease. Arch Neurol. 2002;59(11):1750–1753.
   Google Scholar
• Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin Emerg Drugs. 2013;18(1):39–53.
   PubMed Web of Science ®Google Scholar
• Sprenger F, Poewe W. Management of motor and non-motor symptoms in Parkinson’s disease. CNS Drugs. 2013;27(4):259–272.
   PubMed Web of Science ®Google Scholar
• Louter M, Aarden WC, Lion J, Bloem BR, Overeem S. Recognition and diagnosis of sleep disorders in Parkinson’s disease. J Neurol. 2012; 259(10):2031–2040.
   Web of Science ®Google Scholar
• Rolinski M, Szewczyk-Krolikowski K, Tomlinson PR, et al. REM sleep behaviour disorder is associated with worse quality of life and other non-motor features in early Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2014;85(5):560–566.
   PubMed Web of Science ®Google Scholar
• Chahine LM, Daley J, Horn S, et al. Association between dopaminergic medications and nocturnal sleep in early-stage Parkinson’s disease. Parkinsonism Relat Disord. 2013;19(10):859–863.
   Web of Science ®Google Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26 Suppl 3:S42–S80.
   Google Scholar
• Kunz D, Mahlberg R. A two-part, double-blind, placebo-controlled trial of exogenous melatonin in REM sleep behaviour disorder. J Sleep Res. 2010;19(4):591–596.
   PubMed Web of Science ®Google Scholar
• Chaudhuri KR, Logishetty K. Dopamine receptor agonists and sleep disturbances in Parkinson’s disease. Parkinsonism Relat Disord. 2009; 15(Suppl 4):S101–S104.
   PubMed Web of Science ®Google Scholar
• Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord. 2008;23(6):837–844.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52(5):784–788.
   PubMed Web of Science ®Google Scholar
• Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697–707.
   PubMed Web of Science ®Google Scholar
• Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain. 2009;132(Pt 11):2958–2969.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology. 2010;75(12):1062–1069.
   PubMed Web of Science ®Google Scholar
• Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26(10):1814–1824.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Picillo M, et al. Side of onset does not influence cognition in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2013;19(2):256–259.
   PubMed Web of Science ®Google Scholar
• Aarsland D, Taylor JP, Weintraub D. Psychiatric issues in cognitive impairment. Mov Disord. 2014;29(5):651–662.
   PubMed Web of Science ®Google Scholar
• Erro R, Santangelo G, Barone P, et al. Do subjective memory complaints herald the onset of mild cognitive impairment in Parkinson disease? J Geriatr Psychiatry Neurol. 2014;27(4):276–281.
   PubMed Web of Science ®Google Scholar
• Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force guidelines. Mov Disord. 2012;27(3):349–356.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Mavandadi S, Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology. 2010;75(5):448–455.
   PubMed Web of Science ®Google Scholar
• Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson’s disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord. 2011;26(10):1851–1858.
   PubMed Web of Science ®Google Scholar
• Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson’s disease. Mov Disord. 2006;21(9):1375–1379.
   PubMed Web of Science ®Google Scholar
• Tan LC. Mood disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(Suppl 1):S74–S76.
   Web of Science ®Google Scholar
• Erro R, Pappatà S, Amboni M, et al. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson’s disease patients. Parkinsonism Relat Disord. 2012;18(9):1034–1038.
   PubMed Web of Science ®Google Scholar
• Starkstein SE, Preziosi TJ, Berthier ML, Bolduc PL, Mayberg HS, Robinson RG. Depression and cognitive impairment in Parkinson’s disease. Brain. 1989;112(Pt 5):1141–1153.
   Google Scholar
• Dissanayaka NNW, Sellbach A, Silburn PA, O’Sullivan JD, Marsh R, Mellick GD. Factors associated with depression in Parkinson’s disease. J Affect Disord. 2011;132(1–2):82–88.
   Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Relationship between depression and cognitive dysfunctions in Parkinson’s disease without dementia. J Neurol. 2009;256(4):632–638.
   PubMed Web of Science ®Google Scholar
• Varanese S, Perfetti B, Ghilardi MF, Di Rocco A. Apathy, but not depression, reflects inefficient cognitive strategies in Parkinson’s disease. PLoS One. 2011;6(3):e17846.
   PubMed Web of Science ®Google Scholar
• Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573–580.
   PubMed Web of Science ®Google Scholar
• Skapinakis P, Bakola E, Salanti G, Lewis G, Kyritsis AP, Mavreas V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol. 2010;10:49.
   PubMed Web of Science ®Google Scholar
• Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psychiatry. 2011;168(10):1066–1074.
   PubMed Web of Science ®Google Scholar
• Pal E, Nagy F, Aschermann Z, Balazs E, Kovacs N. The impact of left prefrontal repetitive transcranial magnetic stimulation on depression in Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Mov Disord. 2010;25(14):2311–2317.
   PubMed Web of Science ®Google Scholar
• Boggio PS, Fregni F, Bermpohl F, et al. Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson’s disease and concurrent depression. Mov Disord. 2005;20(9):1178–1184.
   PubMed Web of Science ®Google Scholar
• Fregni F, Santos CM, Myczkowski ML, et al. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(8):1171–1174.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Trojano L, Barone P, Errico D, Grossi D, Vitale C. Apathy in Parkinson’s disease: diagnosis, neuropsychological correlates, pathophysiology and treatment. Behav Neurol. 2013;27(4):501–513.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Neuropsychological correlates of theory of mind in patients with early Parkinson’s disease. Mov Disord. 2012;27(1):98–105.
   Web of Science ®Google Scholar
• Grossi D, Santangelo G, Barbarulo AM, et al. Apathy and related executive syndromes in dementia associated with Parkinson’s disease and in Alzheimer’s disease. Behav Neurol. 2013;27(4):515–522.
   PubMed Web of Science ®Google Scholar
• Santangelo G, Vitale C, Trojano L, et al. Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson’s disease: a prospective longitudinal study. Eur J Neurol. May 22. doi: 10.1111/ene.12467. [Epub ahead of print].
   Google Scholar
• Isella V, Iurlaro S, Piolti R, et al. Physical anhedonia in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2003;74(9):1308–1311.
   Web of Science ®Google Scholar
• Matsui K, Tachibana H, Yamanishi T, et al. Clinical correlates of anhedonia in patients with Parkinson’s disease. Clin Neurol Neurosurg. 2013;115(12):2524–2527.
   PubMed Web of Science ®Google Scholar
• Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73(6):636–642.
   PubMed Web of Science ®Google Scholar
• Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson’s disease. J Neurol Sci. 2006;248(1–2):266–270.
   Web of Science ®Google Scholar
• Santangelo G, Morgante L, Savica R, et al; PRIAMO Study Group. Anhedonia and cognitive impairment in Parkinson’s disease: Italian validation of the Snaith-Hamilton Pleasure Scale and its application in the clinical routine practice during the PRIAMO study. Parkinsonism Relat Disord. 2009;15(8):576–581.
   Web of Science ®Google Scholar
• Reichmann H, Odin P, Brecht HM, Köster J, Kraus PH. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl. 2006;(71):17–25.
   PubMedGoogle Scholar
• Ray Chaudhuri K, Martinez-Martin P, Antonini A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19(7):660–665.
   PubMed Web of Science ®Google Scholar
• Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson’s disease: definition, epidemiology, risk factors, neurobiology and management. Parkinsonism Relat Disord. 2009;15 Suppl 4:S111–S115.
   Google Scholar
• Djamshidian A, Averbeck BB, Lees AJ, O’Sullivan SS. Clinical aspects of impulsive compulsive behaviours in Parkinson’s disease. J Neurol Sci. 2011;310(1–2):183–188.
   Web of Science ®Google Scholar
• Lim SY, Tan ZK, Ngam PI, et al. Impulsive-compulsive behaviors are common in Asian Parkinson’s disease patients: assessment using the QUIP. Parkinsonism Relat Disord. 2011;17(10):761–764.
   Web of Science ®Google Scholar
• Antonini A, Siri C, Santangelo G, et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson’s disease. Mov Disord. 2011;26(3):464–468.
   Web of Science ®Google Scholar
• Santangelo G, Barone P, Trojano L, Vitale C. Pathological gambling in Parkinson’s disease. A comprehensive review. Parkinsonism Relat Disord. 2013;19(7):645–653.
   PubMed Web of Science ®Google Scholar
• Vitale C, Santangelo G, Trojano L, et al. Comparative neuropsychological profile of pathological gambling, hypersexuality, and compulsive eating in Parkinson’s disease. Mov Disord. 2011;26(5):830–836.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Association of dopamine agonists use with impulse control disorders in Parkinson’s disease. Arch Neurol. 2006;63(7):969–973.
   PubMedGoogle Scholar
• Voon V, Thomsen T, Miyasaki JM, et al. Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol. 2007;64(2):212–216.
   PubMedGoogle Scholar
• Voon V, Sohr M, Lang AE, et al. Impulse control disorders in Parkinson disease: a multicenter case – control study. Ann Neurol. 2011;69(6):986–996.
   PubMed Web of Science ®Google Scholar
• Driver-Dunckley E, Samanta J, Stacy M. Pathological gambling associated with dopamine agonist therapy in Parkinson’s disease. Neurology. 2003;61(3):422–423.
   PubMed Web of Science ®Google Scholar
• Dodd ML, Klos KJ, Bower JH, Geda YE, Josephs KA, Ahlskog JE. Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol. 2005;62(9):1377–1381.
   PubMedGoogle Scholar
• Weintraub D, Sohr M, Potenza MN, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68(6):963–968.
   PubMed Web of Science ®Google Scholar
• Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68(3):400–404.
   PubMed Web of Science ®Google Scholar
• Grant JE, Potenza MN. Impulse control disorders: clinical characteristics and pharmacological management. Ann Clin Psychiatry. 2004; 16(1):27–34.
   PubMedGoogle Scholar
• Fong T, Kalechstein A, Bernhard B, Rosenthal R, Rugle L. A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers. Pharmacol Biochem Behav. 2008;89(3):298–303.
   PubMed Web of Science ®Google Scholar
• Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson’s disease with dopaminergic agents. Depress Anxiety. 2000;11(4):185–186.
   PubMed Web of Science ®Google Scholar
• Bostwick JM, Hecksel KA, Stevens SR, Bower JH, Ahlskog JE. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84(4):310–316.
   PubMed Web of Science ®Google Scholar
• Rotondo A, Bosco D, Plastino M, Consoli A, Bosco F. Clozapine for medication-related pathological gambling in Parkinson disease. Mov Disord. 2010;25(12):1994–1995.
   PubMed Web of Science ®Google Scholar
• Sevincok L, Akoglu A, Akyol A. Quetiapine in a case with Parkinson disease and pathological gambling. J Clin Psychopharmacol. 2007;27(1):107–108.
   Web of Science ®Google Scholar
• Hicks CW, Pandya MM, Itin I, Fernandez HH. Valproate for the treatment of medication-induced impulse-control disorders in three patients with Parkinson’s disease. Parkinsonism Relat Disord. 2011;17(5):379–381.
   PubMed Web of Science ®Google Scholar
• Bermejo PE. Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2008;14(5):448–449.
   PubMed Web of Science ®Google Scholar
• Bermejo PE, Ruiz-Huete C, Anciones B. Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol. 2010; 257(10):1682–1685.
   PubMed Web of Science ®Google Scholar
• Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology. 1988;38(8):1237–1244.
   PubMed Web of Science ®Google Scholar
• Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol. 2008;63(2):167–173.
   PubMed Web of Science ®Google Scholar
• Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res. 2004;318(1):121–134.
   PubMed Web of Science ®Google Scholar
• Wolters ECh, Braak H. Parkinson’s disease: premotor clinico-pathological correlations. J Neural Transm Suppl. 2006;(70):309–319.
   Google Scholar
• Doty RL. The olfactory vector hypothesis of neurodegenerative disease: is it viable? Ann Neurol. 2008;63(1):7–15.
   PubMed Web of Science ®Google Scholar
• Picillo M, Pellecchia MT, Erro R, et al. The use of University of Pennsylvania Smell Identification Test in the diagnosis of Parkinson’s disease in Italy. Neurol Sci. 2014;35(3):379–383.
   PubMed Web of Science ®Google Scholar
• Markopoulou K, Larsen KW, Wszolek EK, et al. Olfactory dysfunction in familial parkinsonism. Neurology. 1997;49(5):1262–1267.
   Web of Science ®Google Scholar
• Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW. Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2010;81(4):396–399.
   PubMed Web of Science ®Google Scholar
• Berendse HW, Roos DS, Raijmakers P, Doty RL. Motor and non-motor correlates of olfactory dysfunction in Parkinson’s disease. J Neurol Sci. 2011;310(1–2):21–24.
   Web of Science ®Google Scholar
• Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in ‘de novo’ parkinsonian patients. Neurology. 1995;45(2):386–387.
   Web of Science ®Google Scholar
• Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology. 2006;66(6):845–851.
   Web of Science ®Google Scholar
• Almer Z, Klein KS, Marsh L, Gerstenhaber M, Repka MX. Ocular motor and sensory function in Parkinson’s disease. Ophthalmology. 2012;119(1):178–182.
   Web of Science ®Google Scholar
• Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson’s disease. J Pediatr Ophthalmol Strabismus. 1996;33(3):144–147.
   PubMed Web of Science ®Google Scholar
• Jones RD, Donaldson IM. Fractionation of visuoperceptual dysfunction in Parkinson’s disease. J Neurol Sci. 1995;131(1):43–50.
   PubMed Web of Science ®Google Scholar
• Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual acuity in Parkinson’s disease. Mov Disord. 1992;7(3):232–238.
   Web of Science ®Google Scholar
• Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2006;19(1):36–40.
   Web of Science ®Google Scholar
• Diederich NJ, Raman R, Leurgans S, Goetz CG. Progressive worsening of spatial and chromatic processing deficits in Parkinson disease. Arch Neurol. 2002;59(8):1249–1252.
   Google Scholar
• Abutan BB, Hoes AW, Van Dalsen CL, Verschuure J, Prins A. Prevalence of hearing impairment and hearing complaints in older adults: a study in general practice. Fam Pract. 1993;10(4):391–395.
   Web of Science ®Google Scholar
• Gawel MJ, Das P, Vincent S, Rose FC. Visual and auditory evoked responses in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1981;44:227–232.
   PubMed Web of Science ®Google Scholar
• Fradis M, Samet A, Ben-David J, et al. Brainstem auditory evoked potentials to different stimulus rates in parkinsonian patients. Eur Neurol. 1988;28(4):181–186.
   Web of Science ®Google Scholar
• Vitale C, Marcelli V, Allocca R, et al. Hearing impairment in Parkinson’s disease: expanding the nonmotor phenotype. Mov Disord. 2012;27(12):1530–1535.
   PubMed Web of Science ®Google Scholar
• Lai SW, Liao KF, Lin CL, Lin CC, Sung FC. Hearing loss may be a non-motor feature of Parkinson’s disease in older people in Taiwan. Eur J Neurol. 2014;21(5):752–757.
   Web of Science ®Google Scholar
• Hagell P, Brundin L. Towards an understanding of fatigue in Parkinson disease. J Neurol Neurosurg Psychiatry. 2009;80(5):489–492.
   PubMed Web of Science ®Google Scholar
• Beiske AG, Loge JH, Hjermstad MJ, Svensson E. Fatigue in Parkinson’s disease: prevalence and associated factors. Mov Disord. 2010;25(14):2456–2460.
   Web of Science ®Google Scholar
• Berardelli A, Conte A, Fabbrini G, et al. Pathophysiology of pain and fatigue in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S226–S228.
   Google Scholar
• Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson’s disease is linked to striatal and limbic serotonergic dysfunction. Brain. 2010;133(11):3434–3443.
   PubMedGoogle Scholar
• Lou JS, Kearns G, Benice T, Oken B, Sexton G, Nutt J. Levodopa improves physical fatigue in Parkinson’s disease: a double-blind, placebo-controlled, crossover study. Mov Disord. 2003;18(10):1108–1114.
   PubMed Web of Science ®Google Scholar
• Abe K, Takanashi M, Yanagihara T, Sakoda S. Pergolide mesilate may improve fatigue in patients with Parkinson’s disease. Behav Neurol. 2001–2002;13(3–4):117–121.
   PubMed Web of Science ®Google Scholar
• Stocchi F; ADAGIO investigators. Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson’s disease. Eur J Neurol. 2014;21(2):357–360.
   Web of Science ®Google Scholar
• Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord. 2007;22(14):2070–2076.
   PubMed Web of Science ®Google Scholar
• O’Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ. Nonmotor symptoms as presenting complaints in Parkinson’s disease: a clinicopathological study. Mov Disord. 2008;23(1):101–106.
   PubMed Web of Science ®Google Scholar
• Beiske AG, Loge JH, Rønningen A, Svensson E. Pain in Parkinson’s disease: Prevalence and characteristics. Pain. 2009;141(1–2):173–177.
   PubMed Web of Science ®Google Scholar
• Nègre-Pagès L, Regragui W, Bouhassira D, Grandjean H, Rascol O; DoPaMiP Study Group. Chronic pain in Parkinson’s disease: the cross-sectional French DoPaMiP survey. Mov Disord. 2008;23(10):1361–1369.
   PubMed Web of Science ®Google Scholar
• Ford B. Pain in Parkinson’s disease. Mov Disord. 2010;25 Suppl 1:S98–S103.
   Google Scholar